Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Pfizer Déjà Vu: Is It Time To Sell The Consumer Health Business?

Executive Summary

As Pfizer re-examines a potential sale of its consumer business, analysts expect it would attract suitors with a likely price of $15bn to $17bn, but also say it might be better off continuing to compete in the sector that accounted for around $3.4bn of its 2016 revenues.


Related Content

Big Pharma Set To Compete For German Merck's Consumer Health Unit
Oral Contraceptive Switch Advocates Reject User Age As Approval Factor
OTC Evolution For Prestige Brands Combines Near- And Long-Term Strategies
Cialis Or Viagra Switch? Sanofi Survey, Pfizer Help Wanted Ad Could Be Signs
Stronger Together: Pfizer Decides Against A Split
Light Still On For Switches After Pfizer Pulls Plug On OTC Lipitor
Lipitor Switch Decision Could Portend Pfizer’s Consumer Product Future
Pfizer Would Explore Where No Other Firm Has Gone Before With Lipitor Switch


Related Companies

Related Deals




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

All set! This Question has been sent to my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts